BioNTech SE Sponsored ADR $BNTX Shares Purchased by CenterBook Partners LP

CenterBook Partners LP raised its stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 97.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 215,944 shares of the company’s stock after acquiring an additional 106,527 shares during the quarter. BioNTech makes up approximately 1.3% of CenterBook Partners LP’s investment portfolio, making the stock its 12th largest position. CenterBook Partners LP owned approximately 0.09% of BioNTech worth $22,992,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Baader Bank Aktiengesellschaft grew its position in shares of BioNTech by 6.3% during the second quarter. Baader Bank Aktiengesellschaft now owns 151,862 shares of the company’s stock worth $16,032,000 after acquiring an additional 9,040 shares during the last quarter. Shell Asset Management Co. grew its position in BioNTech by 15.3% during the 2nd quarter. Shell Asset Management Co. now owns 40,610 shares of the company’s stock worth $4,324,000 after purchasing an additional 5,398 shares during the last quarter. Swedbank AB acquired a new position in BioNTech in the first quarter valued at $3,415,000. Millennium Management LLC raised its holdings in shares of BioNTech by 252.5% in the first quarter. Millennium Management LLC now owns 544,970 shares of the company’s stock valued at $49,625,000 after buying an additional 390,360 shares during the last quarter. Finally, Allianz SE boosted its stake in shares of BioNTech by 635.0% during the second quarter. Allianz SE now owns 5,880 shares of the company’s stock worth $626,000 after buying an additional 5,080 shares during the period. 15.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have weighed in on BNTX shares. HC Wainwright increased their price objective on BioNTech from $136.00 to $140.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Jefferies Financial Group reissued a “buy” rating on shares of BioNTech in a report on Wednesday, November 12th. Cowen reiterated a “hold” rating on shares of BioNTech in a research report on Monday, November 3rd. Morgan Stanley reissued an “overweight” rating and set a $134.00 price target on shares of BioNTech in a research report on Monday, November 3rd. Finally, Bank of America cut their price objective on shares of BioNTech from $134.00 to $130.00 and set a “buy” rating for the company in a research report on Wednesday, October 22nd. Ten equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, BioNTech presently has an average rating of “Moderate Buy” and a consensus price target of $135.20.

BioNTech Stock Down 1.4%

Shares of NASDAQ:BNTX opened at $95.59 on Friday. The stock has a market capitalization of $22.99 billion, a price-to-earnings ratio of -59.74 and a beta of 1.54. BioNTech SE Sponsored ADR has a 1-year low of $81.20 and a 1-year high of $129.27. The company’s fifty day moving average is $102.76 and its two-hundred day moving average is $104.82. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.48 and a current ratio of 8.61.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Monday, November 3rd. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of $0.75 by ($0.89). BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The company had revenue of $1.78 billion during the quarter, compared to analyst estimates of $1.21 billion. During the same period in the prior year, the business earned $0.81 earnings per share. BioNTech’s quarterly revenue was up 22.0% on a year-over-year basis. BioNTech has set its FY 2025 guidance at EPS. Equities analysts anticipate that BioNTech SE Sponsored ADR will post -3.88 EPS for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.